The SBI Healthcare Opportunities Fund has delivered a 14.1% return over the past three months, outperforming several peers. While the fund shows consistent momentum, investors should note the very high risk associated with sectoral funds. Because these funds focus on a single industry, they are sensitive to specific regulatory and market shifts that do not affect broader, diversified portfolios.
The SBI Healthcare Opportunities Fund has emerged as a top performer among healthcare and pharmaceutical mutual funds, recording a return of 14.1% over the last three months. This short-term success is part of a longer trend of consistent performance, where the fund has also outpaced its peers over six-month, one-year, and three-year periods. As of August 2026, the fund continues to maintain a lead over other funds in the category, such as the DSP Healthcare Fund and the Mirae Asset Healthcare Fund.
The fund’s strategy involves concentrated investments in the healthcare and pharmaceutical sector, which includes major players like Sun Pharmaceutical Industries, Divi's Laboratories, Apollo Hospitals Enterprise, and Max Healthcare Institute. With assets under management (AUM) of approximately ₹4,997 crore, the fund is a significant player in the market. Its performance is benchmarked against the BSE Healthcare Index, and it has frequently outperformed this benchmark, demonstrating the results of its specific investment strategy.
However, it is important for investors to understand the nature of sectoral funds before comparing them with broader equity funds. Because the SBI Healthcare Opportunities Fund invests only in healthcare companies, its performance is tied directly to the health of that single sector. This creates a high level of risk known as concentration risk. Unlike a diversified fund, which spreads risk across banking, IT, manufacturing, and other sectors, this fund has no such buffer. If the pharmaceutical sector faces a downturn, the fund’s value can drop significantly and more sharply than the general market.
The sector itself is prone to unique challenges. Pharmaceutical companies often deal with strict regulatory oversight, such as drug pricing caps imposed by the government, FDA audit results for manufacturing plants, and changing healthcare policies. These factors can influence stock prices regardless of how well the company is managed. Consequently, this fund is categorized as a 'Very High' risk investment. It is generally not considered suitable for conservative investors looking for stable or low-volatility returns.
Investors should also consider the operational costs, such as the exit load. The fund currently applies an exit load of 0.50% if units are redeemed within 15 days of purchase, which acts as a cost for investors looking to make very short-term moves. Given these factors, the key monitorable for current and potential investors is not just the recent returns, but the long-term outlook for the healthcare sector, including upcoming regulatory updates and the performance of key companies within the fund’s portfolio.